vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and BLACKLINE, INC. (BL). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $183.2M, roughly 1.6× BLACKLINE, INC.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 2.7%, a 93.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 8.1%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.9%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.
ACAD vs BL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $183.2M |
| Net Profit | $273.6M | $4.9M |
| Gross Margin | 90.8% | 75.2% |
| Operating Margin | 6.1% | 3.7% |
| Net Margin | 96.3% | 2.7% |
| Revenue YoY | 9.4% | 8.1% |
| Net Profit YoY | 90.3% | -91.3% |
| EPS (diluted) | $1.61 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $183.2M | ||
| Q3 25 | $278.6M | $178.3M | ||
| Q2 25 | $264.6M | $172.0M | ||
| Q1 25 | $244.3M | $166.9M | ||
| Q4 24 | $259.6M | $169.5M | ||
| Q3 24 | $250.4M | $165.9M | ||
| Q2 24 | $242.0M | $160.5M | ||
| Q1 24 | $205.8M | $157.5M |
| Q4 25 | $273.6M | $4.9M | ||
| Q3 25 | $71.8M | $5.3M | ||
| Q2 25 | $26.7M | $8.3M | ||
| Q1 25 | $19.0M | $6.1M | ||
| Q4 24 | $143.7M | $56.4M | ||
| Q3 24 | $32.8M | $17.2M | ||
| Q2 24 | $33.4M | $76.7M | ||
| Q1 24 | $16.6M | $10.8M |
| Q4 25 | 90.8% | 75.2% | ||
| Q3 25 | 92.2% | 75.1% | ||
| Q2 25 | 92.2% | 75.2% | ||
| Q1 25 | 91.7% | 75.5% | ||
| Q4 24 | 91.6% | 75.6% | ||
| Q3 24 | 92.5% | 75.2% | ||
| Q2 24 | 92.5% | 74.9% | ||
| Q1 24 | 88.8% | 75.2% |
| Q4 25 | 6.1% | 3.7% | ||
| Q3 25 | 12.8% | 4.3% | ||
| Q2 25 | 12.2% | 4.4% | ||
| Q1 25 | 7.9% | 2.1% | ||
| Q4 24 | 59.1% | 3.7% | ||
| Q3 24 | 12.6% | 5.0% | ||
| Q2 24 | 12.6% | 1.4% | ||
| Q1 24 | 7.4% | 1.1% |
| Q4 25 | 96.3% | 2.7% | ||
| Q3 25 | 25.8% | 3.0% | ||
| Q2 25 | 10.1% | 4.8% | ||
| Q1 25 | 7.8% | 3.6% | ||
| Q4 24 | 55.4% | 33.3% | ||
| Q3 24 | 13.1% | 10.4% | ||
| Q2 24 | 13.8% | 47.8% | ||
| Q1 24 | 8.0% | 6.9% |
| Q4 25 | $1.61 | $0.07 | ||
| Q3 25 | $0.42 | $0.09 | ||
| Q2 25 | $0.16 | $0.13 | ||
| Q1 25 | $0.11 | $0.10 | ||
| Q4 24 | $0.86 | $0.79 | ||
| Q3 24 | $0.20 | $0.27 | ||
| Q2 24 | $0.20 | $0.22 | ||
| Q1 24 | $0.10 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $390.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $332.3M |
| Total Assets | $1.6B | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $390.0M | ||
| Q3 25 | $258.0M | $419.9M | ||
| Q2 25 | $253.6M | $459.1M | ||
| Q1 25 | $217.7M | $479.5M | ||
| Q4 24 | $319.6M | $885.9M | ||
| Q3 24 | $155.1M | $725.3M | ||
| Q2 24 | $177.1M | $616.6M | ||
| Q1 24 | $204.7M | $331.4M |
| Q4 25 | $1.2B | $332.3M | ||
| Q3 25 | $917.3M | $328.3M | ||
| Q2 25 | $822.4M | $414.0M | ||
| Q1 25 | $765.2M | $417.9M | ||
| Q4 24 | $732.8M | $446.7M | ||
| Q3 24 | $577.2M | $367.9M | ||
| Q2 24 | $516.7M | $325.8M | ||
| Q1 24 | $464.0M | $279.8M |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $976.9M | $1.7B | ||
| Q2 24 | $914.1M | $1.9B | ||
| Q1 24 | $855.1M | $2.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $26.7M |
| Free Cash FlowOCF − Capex | — | $26.1M |
| FCF MarginFCF / Revenue | — | 14.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 5.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | $161.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $26.7M | ||
| Q3 25 | $74.3M | $63.8M | ||
| Q2 25 | $64.0M | $32.3M | ||
| Q1 25 | $20.3M | $46.7M | ||
| Q4 24 | $40.4M | $43.8M | ||
| Q3 24 | $63.2M | $55.9M | ||
| Q2 24 | $25.0M | $40.7M | ||
| Q1 24 | $29.1M | $50.4M |
| Q4 25 | — | $26.1M | ||
| Q3 25 | $73.9M | $63.3M | ||
| Q2 25 | — | $31.4M | ||
| Q1 25 | — | $40.8M | ||
| Q4 24 | — | $43.0M | ||
| Q3 24 | $63.2M | $55.5M | ||
| Q2 24 | — | $40.0M | ||
| Q1 24 | — | $50.1M |
| Q4 25 | — | 14.2% | ||
| Q3 25 | 26.5% | 35.5% | ||
| Q2 25 | — | 18.2% | ||
| Q1 25 | — | 24.4% | ||
| Q4 24 | — | 25.4% | ||
| Q3 24 | 25.2% | 33.5% | ||
| Q2 24 | — | 24.9% | ||
| Q1 24 | — | 31.8% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 0.1% | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | -0.18× | 5.46× | ||
| Q3 25 | 1.03× | 12.07× | ||
| Q2 25 | 2.40× | 3.90× | ||
| Q1 25 | 1.07× | 7.72× | ||
| Q4 24 | 0.28× | 0.78× | ||
| Q3 24 | 1.93× | 3.24× | ||
| Q2 24 | 0.75× | 0.53× | ||
| Q1 24 | 1.76× | 4.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
